PBLS Leads a Three-Buy Insider Week (2026)

The July 20–27, 2026 screen found three officer/director-linked Form 4 purchase signals above $1 million, totaling $10.50 million. RA Capital Management supplied the two largest qualifying rows: a $6.92 million PBLS purchase on July 20 and a $2.58 million ARTV purchase on July 21. Pinnacle Financial Partners Chief Banking Officer Robert A. McCabe Jr. just cleared the line with a $1.000 million purchase on July 24.

The noisy headline was Five Star Bancorp: at least two directors bought $5.63 million at the same $44 price, alongside several smaller director purchases. But Five Star had also priced a 2.725 million-share public offering at $44 on July 22, so that cluster is excluded from the clean tally rather than presented as discretionary open-market conviction.

Screen window: July 20 at 8:00 a.m. through July 27 at 8:00 a.m., UTC-5. Dollar values are gross reported purchase values. “P” means the screener classified the row as a purchase; it does not by itself prove that every transaction was executed on a public exchange.

The three qualifying rows

Rank	Company	Insider and role	Reported purchase	July 24 close / snapshot	Read-through
1	Parabilis Medicines (PBLS)	RA Capital Management, L.P.; Director, 10% holder	244,593 shares at $28.29 = $6,919,551 on July 20	$31.28, about +10.6% from the reported price; market cap about $3.70B	Largest signal, but an investment vehicle rather than an operating executive
2	Artiva Biotherapeutics (ARTV)	RA Capital Management, L.P.; Director, 10% holder	264,586 shares at $9.76 = $2,583,314 on July 21	$10.03, about +2.8% from the reported price; market cap about $487M	Repeat accumulation; no new company catalyst was verified within ±14 days
3	Pinnacle Financial Partners (PNFP)	Robert A. McCabe Jr.; Chief Banking Officer	10,013 shares at a $99.90 weighted average = $1,000,299 on July 24	$102.60, about +2.7% from the reported price; market cap about $7.15B	Direct, near-threshold purchase two sessions after the Q2 release

The price changes above compare the reported purchase price with the last available regular-session close before the cutoff. They are marks, not realized returns, and exclude dividends, fees and any intraday execution differences. Company sectors are Health Technology/Pharmaceuticals for PBLS, Health Technology/Biotechnology for ARTV, and Finance/Regional Banks for PNFP. The market and close snapshots come from the run’s iTick data; quote pages are linked for reader reference: 1 2 3

1. PBLS: the largest qualifying purchase, with a financing-history caveat

OpenInsider records RA Capital Management, L.P. as a Director, 10% holder and classifies the July 20 PBLS row as P – Purchase: 244,593 shares at $28.29, worth $6.92 million. That makes it the week’s largest in-scope signal, but the identity matters. This is a large investment vehicle/board-holder purchase, not a CEO or CFO transaction. 4

The stock’s $31.28 July 24 close was 10.6% above the reported purchase price. No material PBLS company announcement was verified in the ±14-day context check around July 20, so the filing supplies the clearest new fact: a large holder added after the stock had already moved well above its June IPO price.

The track record is difficult to score cleanly. RA Capital’s page shows a $423.8 million PBLS purchase on June 11, but Parabilis’ own release identifies that date as the IPO closing: 38.525 million shares were sold at $20, alongside a concurrent 4.166-million-share private placement to Regeneron at $18. That earlier entry is financing-related and should not be treated as a comparable open-market timing call. 5 6

Track-record read: positive mark since the July 20 purchase, but no dependable six-to-twelve-month predictive record can be inferred from the available RA Capital/PBLS history because the largest prior entry was an IPO/private-financing allocation.

2. ARTV: a repeat buyer, not a one-off filing

The ARTV row is also RA Capital, again reported as Director, 10% and coded P – Purchase. The July 21 filing covered 264,586 shares at $9.76, or $2.58 million. RA Capital also reported a separate $1.43 million ARTV purchase on July 16, but that trade falls outside this week’s July 20–27 window and is not added to the weekly total. 7

This is the clearest repeat-buying pattern in the screen. The same insider page shows ARTV purchases on June 9, June 12, June 25, July 10, July 16 and July 21, with the earlier large rows at $7.44, $8.66 and $8.93. Against the July 24 close of $10.03, those earlier marks are positive, but the history is only weeks long and sits inside a volatile clinical-stage biotechnology name. It is evidence of persistence, not a proven six-to-twelve-month hit rate. 5

Artiva’s strongest publicly documented clinical backdrop in the source record is earlier than the current window: its May 8 release reported initial AlloNK data and FDA alignment on a single Phase 3 registrational trial design in refractory rheumatoid arthritis. No new company catalyst was identified between July 7 and August 4, so the July 21 purchase cannot be cleanly tied to a fresh announcement. 8

Track-record read: the current position is modestly above the reported purchase price, and repeated buying is a stronger signal than a single print. Still, the short observation window and clinical-event risk argue against calling the pattern predictive.

3. PNFP: an exact-threshold officer purchase after earnings

Robert A. McCabe Jr., Pinnacle’s Chief Banking Officer and a director, reported a July 24 purchase of 10,013 common shares at a $99.90 weighted-average price. The filing page says the trades ranged from $99.67 to $100.00, were held directly, and were not made pursuant to a Rule 10b5-1 plan. The gross value was $1,000,299 — only $299 above the channel’s strict $1 million threshold. 9

PNFP released second-quarter results on July 22, two trading sessions before the purchase. The company reported $313 million of net income available to common shareholders and diluted EPS of $2.07; adjusted diluted EPS was $2.50. That timing is useful context, but it does not establish that the purchase was a response to the release. 10

The July 24 close of $102.60 was about 2.7% above the weighted-average purchase price. The trailing screen shows only one earlier PNFP P-code purchase, a $94,520 CFO buy in February, so there is no meaningful >$1 million personal-buying series from which to estimate McCabe’s hit rate. Track-record read: clean filing mechanics and positive initial mark, but an untested signal at this size.

What was excluded

FSBC: a real cluster, but tied to a public offering

Five Star Bancorp produced a notable same-price cluster on July 22. Larry Eugene Allbaugh, a director and 10% holder, reported 96,591 shares at $44 for $4.25 million through trusts. Robert Truxtun Perry-Smith, a director, reported 31,363 shares at $44 for $1.38 million. Other directors also reported smaller purchases at the same price, making this a cluster rather than an isolated print. 11 12

The problem is price provenance. Five Star announced a 2.725 million-share underwritten public offering at $44 on July 22, with an underwriter option for another 408,750 shares and expected net proceeds of about $112.9 million. The Form 4 summaries describe the insider transactions as “open market or private” and show indirect trust ownership; they do not resolve the public-market-versus-offering question. We therefore exclude the $5.63 million in above-threshold FSBC rows from the clean tally and flag it as a financing-linked cluster. 13

Other screen results

COE’s $10.49 million Jack Huang purchase was dated July 14, before this window. Columbia Financial’s July 20 officer/director rows were below $1 million individually. No additional officer/director purchase above the threshold appeared in the available weekly officer screen.

Source and classification note

This is a strict screen of reported Form 4 purchase rows: option exercises, gifts, derivative-marked rows, and financing artifacts are not counted as clean open-market signals. OpenInsider’s SEC-linked pages supplied the breadth screen; StockTitan’s parsed Form 4 pages supplied the FSBC and PNFP details where the direct SEC XML pages were not readable for this edition. The latter are secondary representations of the filings, so the FSBC classification is intentionally conservative.

A large insider purchase is a signal about disclosed behavior, not a forecast. The useful distinction this week is not simply $10.50 million versus $5.63 million; it is three P-code rows that remain interpretable after checking dates and financing context, versus a bigger cluster whose execution channel is unresolved.

PBLS Leads a Three-Buy Insider Week